deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03766685

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis

Sponsor: UCB Biopharma SRL

Conditions Chronic Plaque Psoriasis Moderate to Severe Chronic Plaque Psoriasis
Interventions Bimekizumab
Updated 19 times since 2019 Last updated: Jul 2, 2025 Started: Dec 20, 2018 Primary completion: Jul 14, 2020 Completion: Sep 8, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03766685, this PHASE3 trial focuses on Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis and remains completed. Sponsored by UCB Biopharma SRL, it has been updated 19 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Nov 2019 · 7 months · monthly snapshot~Nov 2019 – ~Jul 2020 · 8 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Sep 2023 · 17 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Aug 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 14 earlier versions

  1. Apr 2022 — Sep 2023 [monthly]

    Completed PHASE3

  2. Feb 2022 — Apr 2022 [monthly]

    Completed PHASE3

  3. Jan 2022 — Feb 2022 [monthly]

    Completed PHASE3

  4. Sep 2021 — Jan 2022 [monthly]

    Completed PHASE3

  5. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE3

  6. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  7. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Nov 2019 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Enrolling By Invitation → Active Not Recruiting

  11. Apr 2019 — Nov 2019 [monthly]

    Enrolling By Invitation PHASE3

  12. Mar 2019 — Apr 2019 [monthly]

    Enrolling By Invitation PHASE3

  13. Feb 2019 — Mar 2019 [monthly]

    Enrolling By Invitation PHASE3

    Status: Not Yet Recruiting → Enrolling By Invitation

  14. Jan 2019 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Dec 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UCB Biopharma SRL
Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alpharetta, United States , Bakersfield, United States , Baton Rouge, United States , Boca Raton, United States , Brighton, United States , East Windsor, United States , Edmonton, Canada , Halifax, Canada , Hamilton, Canada , Houston, United States and 27 more locations